Noxopharm Ltd has released a press release.
NOX to support expanded LuPIN study
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- Nyrada-Key progress with cholesterol-lowering drug candidate
- VEYONDA - Registered Trade Mark for NOX66
- Release of DARRT-1 Preliminary Safety Data
- Pre-Clinical data confirms Radio-Enhancing potential
- End-of-Study Clinical Data shows benefit of NOX66
Later from Noxopharm
- NOX Subsidiary Announces Important Drug Discovery
- Change of Registry Address: Automic P/L - Sydney Office
- Appendix 4C - quarterly
- NOX to Present Clinical Data at COSA Annual Meeting
- NOX announces Positive Data from CEP-1 Study of Veyonda
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm